Burrell Terry-Ann
Known title: DirectorCIK: 0001786484
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Transaction History
| RXRX | ▲ Buy | Grant | 1,843 | $0 | 7/1/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 13,097 | $0 | 6/3/2024 | View on chart |
| BEAM | ▲ Buy | Grant | 12,500 | $0 | 4/26/2024 | View on chart |
| RXRX | ▲ Buy | Grant | 1,467 | $0 | 4/1/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 5,446 | $175K | 4/1/2024 | View on chart |
| BEAM | ▲ Buy | Grant | 27,500 | $0 | 3/31/2024 | View on chart |
| RXRX | ▼ Sell | Open Market | 8,275 | $104K | 7/13/2023 | View on chart |
| RXRX | ▼ Sell | Open Market | 3,157 | $44K | 7/12/2023 | View on chart |
| RXRX | ▼ Sell | Open Market | 3,195 | $42K | 7/12/2023 | View on chart |
| RXRX | ▼ Sell | Open Market | 78,071 | $948K | 7/12/2023 | View on chart |
| RXRX | ▼ Sell | Open Market | 24,302 | $273K | 7/12/2023 | View on chart |
| RXRX | ▲ Buy | Grant | 12,612 | $0 | 6/16/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 2,186 | $64K | 4/4/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 2,454 | $74K | 4/3/2023 | View on chart |
| BEAM | ▲ Buy | Grant | 20,000 | $0 | 3/31/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 36,152 | $495K | 1/27/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 36,152 | $1.6M | 1/27/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 1,102 | $15K | 1/26/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,102 | $50K | 1/26/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 14,810 | $203K | 1/24/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 14,810 | $667K | 1/24/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 5,426 | $74K | 1/23/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 5,426 | $244K | 1/23/2023 | View on chart |
| BEAM | ▲ Buy | Option Exercise | 39,886 | $546K | 1/18/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 47,195 | $2.1M | 1/18/2023 | View on chart |
| RXRX | ▲ Buy | Grant | 1,821 | $0 | 1/3/2023 | View on chart |
| RXRX | ▲ Buy | Grant | 1,265 | $0 | 10/3/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 1,631 | $0 | 7/1/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 18,145 | $0 | 6/14/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 1,788 | $0 | 4/1/2022 | View on chart |
| BEAM | ▲ Buy | Grant | 15,000 | $0 | 3/31/2022 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,787 | $106K | 3/31/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 763 | $0 | 1/3/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 629 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings
Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.